(Q37656202)

21 August 2017

title

Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer (English)

1 reference

Katherine A Lyseng-Williamson

21 August 2017

1 reference

series ordinal

1

object named as

Katherine A Lyseng-Williamson

1 reference

21 August 2017

publication date

1 January 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

28

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

75-92

1 reference

https://scigraph.springernature.com/pub.10.2165/10482880-000000000-00000

21 August 2017

exact match

0 references

cites work

An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer.

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F10482880-000000000-00000

Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F10482880-000000000-00000

Epidermal growth factor receptor inhibitors in non-small cell lung cancer

21 January 2018

1 reference

12 December 2020

Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Second-line treatment of advanced non-small cell lung cancer

1 reference

12 December 2020

Metastatic non-small cell lung cancer: costs associated with disease progression.

1 reference

12 December 2020

Cost of lung cancer: a methodological review.

1 reference

12 December 2020

Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).

1 reference

12 December 2020

Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

12 December 2020

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

12 December 2020

Health state utilities for non small cell lung cancer

1 reference

12 December 2020

Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.

1 reference

12 December 2020

Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.

1 reference

12 December 2020

The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer

1 reference

12 December 2020

Second-line and third-line chemotherapy for lung cancer: use and cost.

1 reference

12 December 2020

Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer

1 reference

12 December 2020

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

12 December 2020

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

12 December 2020

Estimates and projections of value of life lost from cancer deaths in the United States

1 reference

12 December 2020

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

12 December 2020

Productivity costs of cancer mortality in the United States: 2000-2020

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.

1 reference

12 December 2020

SEOM guidelines for the management of non-small-cell lung cancer (NSCLC)

1 reference

12 December 2020

Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics.

1 reference

12 December 2020

Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

1 reference

12 December 2020

10.2165/10482880-000000000-00000

Identifiers

DOI

1 reference

21 August 2017

1 reference